思力华已在我国获批上市，慢阻肺患者迎福音

Chronic obstructive pulmonary disease (COPD), as one of the most common diseases of the respiratory system, kills 1.28 million people in my country every year, and its prevalence among people over 40 years old is as high as 8.2%. The clinical characteristics of this disease are mainly airflow limitation, which shows progressive and irreversible development, with relatively high morbidity and mortality, which increases the psychological and economic pressure of patients. Respimat is a new environmentally friendly Spiriva spray. Its "soft mist" feature may allow patients to inhale aerosolized fine particles more comfortably, promoting drug deposition in the lungs to about 50%, thereby achieving ideal therapeutic effects, improving the patient's lung function level, and improving the patient's clinical manifestations of dyspnea. In addition, SRIVA Respimat and SRIVA Dry Powder Inhaler 18 u g/d have similar effects and have fewer adverse reactions. Silihua has been approved for marketing in my country, which is good news for domestic COPD patients.

Siliva is a competitive M receptor antagonist. Its main pharmacological effect is to antagonize M3 choline receptors on airway smooth muscles, inhibit the effect of cholinergic nerves on airway smooth muscles, promote smooth muscle relaxation, and dilate bronchi. At the same time, because Siliva is less absorbed throughout the body, it has good safety. Since 2004, Spirava has been widely used for COPD patients in powder inhalation dosage form. In 2014, Spirava spray (Repimat) was launched in my country as a new dosage form because it can be easily inhaled; the drug is efficiently deposited in the lungs; it is easy to carry and is widely used in clinical applications.

For: Respimat is effective 24 hours a day, so use it only once a day, and if possible, at the same time every day. Spray twice with each use. Common adverse reactions include dizziness, high blood pressure, irregular heartbeat, rapid heartbeat, cough, headache, heartbeat sensation, difficulty sleeping, constipation, etc.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.